Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Enhancing Biosimilar Adoption in Value-Based Oncology Care

February 16th 2025

By Travis Brewer

Video

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD

February 15th 2025

By Deana Ferreri, PhD

Article

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

Biosimilars Fuel Price Cuts in European Insulin Glargine Markets

February 14th 2025

By Skylar Jeremias

Article

Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.

The Top 5 Biosimilar Articles for the Week of February 10

February 14th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 10, 2025.

Robert F. Kennedy Jr Confirmed as HHS Secretary, Nearly Along Party Lines

February 13th 2025

By Christina Mattina

Article

The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major changes in pursuit of his Make America Healthy Again agenda.

Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

By Skylar Jeremias

Article

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.

The Future of Pharmacy: Trends, Threats, Transformations

February 11th 2025

By Cameron Santoro

Article

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

By Dracey Poore

Article

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.

Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals

February 9th 2025

By Skylar Jeremias

Podcast

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

February 8th 2025

By Deana Ferreri, PhD

Article

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.